Humacyte Inc (NASDAQ: HUMA) on Monday, plunged -4.77% from the previous trading day, before settling in for the closing price of $4.61. Within the past 52 weeks, HUMA’s price has moved between $2.48 and $9.97.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company achieved an average annual earnings per share of -26.44%. With a float of $104.37 million, this company’s outstanding shares have now reached $119.84 million.
The extent of productivity of a business whose workforce counts for 183 workers is very important to gauge. In terms of profitability, gross margin is 35.2%, operating margin of -1042.56%, and the pretax margin is -1416.75%.
Humacyte Inc (HUMA) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Humacyte Inc is 18.88%, while institutional ownership is 27.92%. The most recent insider transaction that took place on Dec 04 ’24, was worth 20,181. In this transaction Director of this company bought 4,600 shares at a rate of $4.39, taking the stock ownership to the 16,950 shares. Before that another transaction happened on Nov 19 ’24, when Company’s President, CEO and Director bought 1,797 for $4.44, making the entire transaction worth $7,979. This insider now owns 243,851 shares in total.
Humacyte Inc (HUMA) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.25 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -26.44% per share during the next fiscal year.
Humacyte Inc (NASDAQ: HUMA) Trading Performance Indicators
Humacyte Inc (HUMA) is currently performing well based on its current performance indicators. A quick ratio of 1.10 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.34, a number that is poised to hit -0.25 in the next quarter and is forecasted to reach -0.85 in one year’s time.
Technical Analysis of Humacyte Inc (HUMA)
The latest stats from [Humacyte Inc, HUMA] show that its last 5-days average volume of 3.44 million was inferior to 3.63 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 17.47%. Additionally, its Average True Range was 0.49.
During the past 100 days, Humacyte Inc’s (HUMA) raw stochastic average was set at 24.82%, which indicates a significant increase from 8.81% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 148.05% in the past 14 days, which was higher than the 95.94% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $4.70, while its 200-day Moving Average is $5.53. Now, the first resistance to watch is $4.58. This is followed by the second major resistance level at $4.76. The third major resistance level sits at $4.95. If the price goes on to break the first support level at $4.21, it is likely to go to the next support level at $4.02. The third support level lies at $3.84 if the price breaches the second support level.
Humacyte Inc (NASDAQ: HUMA) Key Stats
Market capitalization of the company is 564.85 million based on 125,859K outstanding shares. Right now, sales total 0 K and income totals -110,780 K. The company made 0 K in profit during its latest quarter, and -39,200 K in sales during its previous quarter.
